EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sotatercept in pulmonary hypertension and beyond

Rosalinda Madonna iD, Sandra Ghelardoni iD

European Journal of Clinical Investigation · 2025-05 · 55 (5)

DOI: 10.1111/eci.14386 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 18.01.2025. Verfasst von Rosalinda Madonna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Recombinant Fusion Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotatercept binds free activins by mimicking the extracellular domain of the activin receptor type IIA (ACTRIIA). Additional ligands are BMP/TGF‐beta, GDF8, GDF11 and BMP10. The binding with activins leads to the inhibition of the signalling pathway and the deactivation of the bone morphogenic protein (BMP) receptor type 2. In this way, sotatercept activates an antiproliferative signalling to the cells of the pulmonary arteries and arterioles with the aim of rebalancing the proliferative and antiproliferative pathway that characterizes the pulmonary arterial hypertension (PAH). Sotatercept is indicated for the treatment of group 1 PAH in combination with drugs that act through the endothelin receptor, nitric oxide or prostacyclin. Its effects, demonstrated in the STELLAR study, are the improvement of exercise capacity and the FC‐WHO functional class, together with the reduction of the risk of clinical worsening events. In addition to its antiremodeling effects on the pulmonary circulation, sotatercept has several haematological effects that could suggest its use in the treatment of some blood disorders other than PAH. In this review, we will discuss the effects of the drug on PAH and in parallel provide an in‐depth overview of its application in haematological disorders, focusing on clinical and preclinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryRecombinant Fusion ProteinsHumansActivin Receptors, Type IISignal TransductionActivinsPulmonary Arterial Hypertension

Stichwörter der Autor:innen

activinsbone morphogenic proteinhaematological disorderspulmonary arterial hyperensionsotatercept

Substanzen

Recombinant Fusion ProteinsActivin Receptors, Type IIActivins

Autor:innen und Institutionen

  • Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.
  • Department of Surgical, Medical and Molecular Pathology and Critical Area, Laboratory of Biochemistry, University of Pisa, Pisa, Italy.

ORCID-Profile: Rosalinda Madonna, Sandra Ghelardoni

Förderung

  • Ministero dell'Università e della Ricerca

Zitieren

APA

Madonna, R., & Ghelardoni, S. (2025). Sotatercept in pulmonary hypertension and beyond. European Journal of Clinical Investigation, 55(5). https://doi.org/10.1111/eci.14386

Vancouver

Madonna R, Ghelardoni S. Sotatercept in pulmonary hypertension and beyond. European Journal of Clinical Investigation. 2025;55(5). doi:10.1111/eci.14386

BibTeX
@article{Madonna2025,
  author = {Madonna, Rosalinda and Ghelardoni, Sandra},
  title = {Sotatercept in pulmonary hypertension and beyond},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  volume = {55},
  number = {5},
  doi = {10.1111/eci.14386}
}
Kostenlos starten →